Toyota Motor's global output increased 11.9 percent on-year to 773,135 vehicles in July, but the growth pace was well below the 41.2 percent gain in June due to the pandemic and a global semiconductor shortage.
While the output growth was for the 11th straight month, the carmaker is expecting a production cut of 40 percent or some 360,000 units in September due to pandemic-caused difficulties in securing components in Southeast Asia, where many suppliers are based.
In Japan, Toyota manufactured 309,138 units, up 21.8 percent.
Toyota's overseas production surged 6.1 percent to 463,997 vehicles, with those from China and other Asian countries increasing 9.1 percent.
In North America, Toyota's production dipped 2.4 percent.
With an increased demand for vehicles in key overseas markets, including North America, Toyota increased sales for the 11th straight month 858,569 vehicles, which is the largest figure for July.


Boeing Wins Fraud Lawsuit Over 737 MAX Filed by LOT Polish Airlines
Oil Prices Jump as U.S. Strikes in Iran Raise Fears Over Strait of Hormuz Supply Disruptions
GameStop Raises eBay Stake to 6.6% as Ryan Cohen Pushes $56 Billion Takeover Bid
Oil Prices Slide as U.S.-Iran Talks Raise Hopes for Strait of Hormuz Reopening
U.S.-Iran Talks May Take Days as Oil Prices React to Strait of Hormuz Tensions
U.S.-Iran Talks Advance as Trump Signals Tough Stance on Hormuz and Nuclear Deal
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market
EU Antitrust Probe Could Lead to Massive Google Fine Under DMA Rules
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says
Gold Prices Slip as Fresh U.S. Strikes on Iran Boost Dollar and Oil Markets
US-Iran Framework Deal Raises Hopes for Strait of Hormuz Reopening
Ferrari Luce: How Ferrari Evolved From Hybrid Supercars to Its First Fully Electric Vehicle
Dollar Weakens as Iran Peace Deal Hopes Boost Global Market Sentiment
OpenAI Eyes IPO Filing as Early as This Week Amid Rising AI Competition
H.B. Fuller Eyes Advanced Medical Solutions in Potential £600M Takeover Deal
NHS shakeup: if it sounds like we’ve been here before, it’s because we have
JPMorgan Sees Large-Cap Biotech Stocks Entering New Growth Phase in 2026 



